Scott Best - Concepedia

Author

Scott Best

Oregon Health & Science University ORCID

Also Known As

Scott Best, Scott R Best, Scott R. Best

Publications

250

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University Millennium Engineering and Integration (United States)City Of Hope National Medical Center Takeda (United States)Dartmouth College

About

Scott Best is an author at Oregon Health & Science University specializing in cell biology, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	90
2	Cell Biology	2	2	90
3	Immunology	2	2	90
4	Autoimmunity	1	1	38
5	Cell Signaling	1	1	52

Scott Best

Publications

218

Citations

H-Index

Page 1

	Year	Citations
Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma Taylor Hashiguchi, Nur Bruss, Scott Best, Molecular Cancer Therapeutics	2019	55
Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells Scott Best, Taylor Hashiguchi, Adam S. Kittai, Blood Advances ApoptosisImmune RegulationImmunologyCell DeathCancer Biology	2019	52
Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells Scott Best, Vi Lam, Tingting Liu, Leukemia Hematological MalignancyImmunomodulatory EffectsNedd8-activating Enzyme InhibitorMalignant Blood DisorderT-regulatory Cell	2020	38
SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia Cody Paiva, Taylor Rowland, Bhargava Sreekantham, Haematologica	2017	32
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells Scott Best, Tingting Liu, Nur Bruss, Leukemia & lymphoma/Leukemia and lymphoma	2019	16
T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia Vi Lam, Carly Roleder, Tingting Liu, Molecular Cancer Therapeutics	2023	14
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia Vi Lam, Scott Best, Adam S. Kittai, British Journal of Clinical Pharmacology	2021	11

Page 1